Please use this identifier to cite or link to this item:
Title: Use of cymelarsan in goats chronically infected with Trypanosoma evansi
Authors: Gutiérrez Cabrera, Carlos Javier 
Corbera Sánchez, Juan Alberto 
Bayou, K.
Van Gool, F.
UNESCO Clasification: 310907 Patología
Keywords: Brucei-Brucei
Mel Cy
Issue Date: 2008
Journal: Annals of the New York Academy of Sciences 
Conference: 9th Biennial Conference on Animal Biodiversity and Emerging Diseases - Prediction and Prevention 
Abstract: Toxicity and therapeutic trials using Cymelarsan (an arsenical compound) against Trypanosoma evansi infection were carried out using chronically infected goats. For the toxicity trial, 40 goats were divided into four groups of 10 animals each; the first three groups received s.c. injections of 5, 10, and 15 mg/kg bw of Cymelarsan, respectively, and the last one served as control. No systemic reaction was observed in any goat throughout the experiment. For the therapeutic trial, 15 adult female goats were inoculated intravenously with at least 1 x 10(5) T evansi isolated in the Canary Islands. Six months after inoculation, the animals were treated with Cymelarsan at single dose of 0.3 mg/kg (5 animals), 0.5 mg/kg (5 animals), and 0.625 mg/kg (5 animals). At 4 and 6 weeks after treatment, two goats belonging to 0.3 mg/kg group showed recurrence of trypanosomes. Parasitemia, however, was negative in all animals belonging to 0.5 and 0.625 mg/kg groups until the end of the experiment (6 months after treatment). Thus, it can be concluded that Cymelarsan is a safe trypanocidal drug for goats and that the curative dose is 0.5 mg/kg or above.
ISBN: 9781573317146
ISSN: 0077-8923
DOI: 10.1196/annals.1428.095
Source: Annals of the New York Academy of Sciences [ISSN 0077-8923], v. 1149 (1), p. 331-333
Appears in Collections:Artículos
Adobe PDF (442,53 kB)
Show full item record

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.